Samrat Pharmachem Share Price
232.70+3.75 (+1.64%)
-27.86% past 1 Year
Corporate filings & documents
Announcements
Notice of 34th AGM - Newspaper Publication
2 weeks agoNotice of 34th AGM - Newspaper Publication
2 weeks agoThe Register of Members and Share Transfer books will remain closed from September 20 2026 To September 22 2026 (both days inclusive)
3 weeks agoThe Register of Members and Share Transfer books will remain closed from September 20 2026 To September 22 2026 (both days inclusive)
3 weeks ago34th Annual General Meeting of the company will be held on Wednesday September 23 2026 at 1:00 PM (IST) through Video Conferencing (VC) / Other Audio Video Means (OAVM)
3 weeks ago34th Annual General Meeting of the company will be held on Wednesday September 23 2026 at 1:00 PM (IST) through Video Conferencing (VC) / Other Audio Video Means (OAVM)
3 weeks ago34th Annual Report for the Financial Year 2025-26
3 weeks ago34th Annual Report for the Financial Year 2025-26
3 weeks agoNewspaper Publication of extract of Standalone Unaudited Financial Results for the quarter ended June 30 2026.
1 month agoNewspaper Publication of extract of Standalone Unaudited Financial Results for the quarter ended June 30 2026.
1 month agoThe Board considered and adopted the unaudited financial results for the quarter ended June 30 2026
1 month agoThe Board considered and adopted the unaudited financial results for the quarter ended June 30 2026
1 month agoAppointment of Statutory Auditors for the company from 34th Annual General Meeting to 39th Annual General Meeting
2 months agoAppointment of Statutory Auditors for the company from 34th Annual General Meeting to 39th Annual General Meeting
2 months agoCertificate under Reg. 74(5) of SEBI (DP) Regulations for the quarter ended 30th June 2026
2 months agoCertificate under Reg. 74(5) of SEBI (DP) Regulations for the quarter ended 30th June 2026
2 months agoSamrat Pharmachem Ltd-has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/08/2026 inter alia to consider and approve Approval of Un-Audited Financial Results for the quarter ended June 30 2026
2 months agoSamrat Pharmachem Ltd-has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/08/2026 inter alia to consider and approve Approval of Un-Audited Financial Results for the quarter ended June 30 2026
2 months agoIntimation of Closure of Trading Window for the quarter ended June 30 2026
2 months agoIntimation of Closure of Trading Window for the quarter ended June 30 2026
2 months agoIntimation of Closure of Trading Window for the quarter ended June 30 2026
2 months agoIntimation of Closure of Trading Window for the quarter ended June 30 2026
2 months agoNewspaper Publication of Extract of the Standalone Audited Financial Results for the year ended March 31 2026.
3 months agoNewspaper Publication of Extract of the Standalone Audited Financial Results for the year ended March 31 2026.
3 months agoThe Board considered and adopted the financial results for the quarter and year ended March 31 2026
3 months agoThe Board considered and adopted the financial results for the quarter and year ended March 31 2026
3 months agoAudited Financial Results for the quarter and year ended 31st March 2026
3 months agoAudited Financial Results for the quarter and year ended 31st March 2026
3 months agoAnnual Secretarial Compliance for the year ended 31-March-2026
3 months agoAnnual Secretarial Compliance for the year ended 31-March-2026
3 months ago<b>Format of Initial Disclosure to be made by an entity identified as a Large Corporate.</b><br/><br/> <table border=1px><tr> <td><b>Sr. No.</b></td> <td><b>Particulars</b></td> <td><b>Details</b></td> </tr> <tr><td>1</td><td>Name of Company</td><td>Samrat Pharmachem Ltd-</td></tr> <tr><td>2</td><td>CIN NO.</td><td>L24230GJ1992PLC017820</td></tr> <tr><td>3</td> <td>Outstanding borrowing of company as on 31st March / 31st December as applicable (in Rs cr)</td> <td>0.00</td></tr> <tr><td>4</td><td>Highest Credit Rating during the previous FY </td><td>-</td></tr> <tr><td>4a</td><td>Name of the Credit Rating Agency issuing the Credit Rating mentioned in (4)</td><td>Not Applicable</td></tr> <tr><td>5</td><td>Name of Stock Exchange# in which the fine shall be paid in case of shortfall in the required borrowing under the framework</td><td>BSE</td></tr> </table> <br/><br/> <div> <div style=float:left;> We confirm that we are a Large Corporate as per the applicability criteria given under the SEBI circular SEBI/HO/DDHS/CIR/P/2018/144 dated November 26 2018. No</div> <br/><br/><br/> <div style=float:left;> Name of the Company Secretary: Nishant Kankaria <br/> Designation: Company Secretary and Compliance Officer <br/> EmailId: [email protected]</div> <div style=float:left;margin-left:50px;> Name of the Chief Financial Officer: Rajesh Mehta <br/> Designation: CFO <br/> EmailId: [email protected]</div> </div> <div> <br/> Date: 07/04/2026<br/><br/> <b>Note:<b> In terms para of 3.2(ii) of the circular beginning F.Y 2022 in the event of shortfall in the mandatory borrowing through debt securities a fine of 0.2% of the shortfall shall be levied by Stock Exchanges at the end of the two-year block period. Therefore an entity identified as LC shall provide in its initial disclosure for a financial year the name of Stock Exchange to which it would pay the fine in case of shortfall in the mandatory borrowing through debt markets. </div>
5 months agoCertificate u/r 74(5) for the quarter ended March 31 2026
5 months agoCertificate u/r 74(5) for the quarter ended March 31 2026
5 months agoCrisil Limited has upgraded its rating to CRISIL BB/STABLE/ CRISILA4+
5 months agoCrisil Limited has upgraded its rating to CRISIL BB/STABLE/ CRISILA4+
5 months agoClosure of Trading Window from 01-04-2026 till 48 hours after the declaration of Audited Financial Results for the year ended 31/03/2026
5 months agoSamrat Pharmachem Ltd-has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 30/05/2026 inter alia to consider and approve the Audited Financial Results for the year ended March 31 2026
5 months agoSamrat Pharmachem Ltd-has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 30/05/2026 inter alia to consider and approve the Audited Financial Results for the year ended March 31 2026
5 months agoNewspaper Publication - Extract of Un-audited financial results for the quarter ended 31 December 2025
7 months agoNewspaper Publication - Extract of Un-audited financial results for the quarter ended 31 December 2025
7 months agoThe Board has considered and took on record the Un-audited financial results of the company for the quarter ended December 31 2025.
7 months agoThe Board has considered and took on record the Un-audited financial results of the company for the quarter ended December 31 2025.
7 months agoThe Board has considered and took on record the un-audited standalone financial results for the quarter ended December 31 2025.
7 months agoCertificate u/r 74(5) for the quarter ended 31/12/2025
8 months agoSamrat Pharmachem Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 13/02/2026 inter alia to consider and approve the un-audited financial results for the quarter ended December 31 2025
8 months agoThe Trading Window of the Company shall remain closed from Thursday January 1 2026 till 48 hours after the declaration of Un-audited financial results for the quarter ended December 31 2025.
8 months agoCrisil Ltd has downgraded its rating to "CrisilBB+/Negative/CrisilA4+"
9 months agoNewspaper Publication - Extract of Results for the quarter and half year ended September 30 2025
10 months agoUn-audited financial results for the quarter and half year ended 30th September 2025
10 months agoThe Board of Directors considered and took on record the Un-audited Standalone Financial Results for the quarter and half year ended September 30 2025.
10 months agoAnnual reports
Concalls & investor presentations
No presentations found